Single-Dose Pharmacokinetics of Ozanimod and Its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study
posted on 2020-08-26, 15:47authored byJonathan Q. Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto, Xiaomin Wang, Maria Palmisano
Article full
text
The article associated with this page has been accepted for
online publication and is in the final stages of production. The link to the
full text will be made available on this page in the next few days.
The above Summary Slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).